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New susceptibility loci associated with Type 2 Diabetes 
 
Nadine A. Mastouri 
Abstract 
 
Type 2 Diabetes (T2D) is a complex multifactorial disease, characterized by insulin resistance 
and a progressive pancreatic β cell failure, leading to an increase in fasting plasma glucose 
level. Up to date and despite the tremendous evolution in genetic research, less than 10% of 
T2D underlying genetic basis has been identified. Hence the whole picture of T2D inheritance is 
not completely exposed yet. So far, the mutations recognized, either through the candidate gene 
approach or recently through the Genome wide association studies, are positioned either in 
genes regulating the insulin resistance pathway or secretion, or in segments of genes of 
unknown function. 
From the most recent mutations identified in 2010, we selected three genes, the Hepatocyte 
Nuclear factor 1-A (HNF1A) (rs7957197), the High mobility group 2 (HMGA2) (rs1531343) 
and the Kruppel-like Factors 14 (KLF14) (rs972283) to be the material of our study. Our aim 
was to identify the polymorphisms related to these genes in the Lebanese diabetic population. 
1205 patients were selected (565 diabetic, 640 control subjects) and were genotyped for 
polymorphisms in HNF1A gene, HMGA2 gene and KLF14 gene. Statistical analysis using chi-
square test was utilized to compare the genotype and allele frequencies between the two groups 
of the study. Our analysis revealed an association between the TT genotype of HNF1A-
rs7957197 and T2D in the Lebanese diabetic population (P = 0.028) but no significant 
correlations were detected for KLF14-rs972283 and the HMGA2-rs1531343  
(P = 0.27 and 0.58 respectively). Furthermore, when considering the treatment with either 
insulin or an Oral hypoglycemic agent, significant results were observed in  
HNF1A-rs7957197, where the risk allele T is more common in patients treated with OHA as 
compared either to a different type of treatment (P = 0.04) or to treatment with insulin injections 
(P = 0.03). Similarly, in KLF14-rs972283 polymorphism the genotype GG was found to be 
correlated with diabetic patients not treated with insulin injections (P = 0.02).  
In conclusion, the HNF1A-rs7957197 and KLF14-rs972283 mutations could be involved in 
attenuating the rate of β cell failure. Further studies with a larger Lebanese sample size must be 
accomplished to confirm our results.                         
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CHAPTER ONE  
INTRODUCTION 
 
1.1. Prevalence of Type 2 Diabetes 
According to the WHO 1999 criteria, Type 2 diabetes (T2D) is a disease 
characterized by an elevated fasting plasma glucose concentration of 126 mg/dl and 
more (Giorgino, Laviola & Leonardini, 2005). Worldwide, over 170 million individuals 
have T2D, and this is expected to increase to 370 million by the year 2025 (Doria, Patti 
& Khan, 2008; Holt, 2004). In harmony with this pattern, the prevalence of diabetes in 
Lebanon has been regularly increasing with time. Being 7-8% in adults over 30 years of 
age in 1969, the frequency increased to 13.1% in 1997 (Salti, Khogali, Alam, Abu 
haidar & Masri, 1997), to 15.8% in 2005 (Hirbli et al. 2005) and to 18.9% of adults 
above 40 years old in 2007 (Kristensen, Bak, Wittrup & Lauritzen, 2007). 
Family, twins and population studies have confirmed that 30-70% of T2D risk is 
due to genetic factors. Monozygotic twins have double the concordance rate for T2D as 
compared to dizygotic twins, and the offspring of one diabetic and two diabetic parents 
show a risk of 35% and 70% respectively, compared to 10% of the population. These 
facts constitute a solid proof regarding the relation between T2D and the genetic 
predisposing factors (Walford & Florez, 2010).  
At the same time, environmental factors and life style, mainly obesity and 
physical inactivity, have an accentuating impact on the disease development (Walford & 
Florz, 2010; Holt, 2004). The constant increase in diabetes frequency worldwide, can 
also be attributed  to an elevation in the obesity rate: in the united states, 67% of patients 
with diabetes have a BMI of more than 27kg/m
2
 and 46% more than 30kg/m
2
 (Holt, 
2004).  
Hence, diabetes is a multifactorial heterogeneous disease, caused by an interaction 
between several genes each of which has, besides the environmental factors, a precise 
effect on the disease development (Walford & Florez, 2010). 
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1.2. Pathophysiology of T2D 
The disease pathophysiology is caused by a peripheral insulin resistance (failure 
of peripheral tissues to respond to insulin) and insulin deficiency due to a decrease in β 
cell functions (Giorgino et al. 2005; lupi & Del Pato, 2008). The initial event in the 
disease is characterized by a deficit in insulin action, followed by an impaired insulin 
secretion (Giorgino et al. 2005). 
  
Figure 1: The interface of environment and genetics with T2D pathogenesis (Giorgino 
et al. Pathophysiology of type 2 diabetes: Rationale for different oral 
antidiabetic treatment strategies. Diabetes research and clinical practice. 
2005; 68S1:S22-S29). 
 
 
1.2.1. Insulin resistance  
Insulin regulates glucose metabolism in the muscles, liver and adipose tissues 
(luca & Olefsky 2007). In the skeletal muscles, it induces glucose uptake in the 
cell through the transfer of glucose transporter 4 (GLUT4) to the plasma 
membrane. In the liver, insulin prevents the activity of the gluconeogenic 
enzymes, and in the adipose tissues, it decreases the activity of the lipase 
Hormone sensitive enzyme (LIPE), causing less hydrolysis of Trigylcerides 
resulting in a decrease in the formation of  free fatty acids (FFA) and their 
release from the adipocytes into the circulation (luca & Olefsky, 2007). 
 
a. Genetic factors 
Insulin resistance is related to environmental factors such as obesity, aging, 
smoking, low physical activity and to underlying genetic causes (Mlinar, Marc, 
Janez & Pfeifer, 2007). The Genome wide associations studies (GWAS) have 
identified the Peroxisome proliferate-activated receptor ϒ (PPARG) gene that 
alters insulin sensitivity. The latter gene is located on the short arm of 
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chromosome 3. It regulates directly the genes involved in lipid metabolism, 
uptake and storage, and glucose metabolism (Jeninga, Gurnell & Kalkhoven, 
2009). PPARϒ, when activated, induces the secretion of adinopectin hormone, 
through the activation of adinopectin gene transcription and that increases insulin 
sensitivity (Jeninga et al. 2009). The mutation from Proline to Alanine at position 
12 (Pro12Ala) is located in the activation function domain 1 (AF-1), within the N-
terminal segment of the gene, and it induces insulin resistance through a decrease 
in the target gene activation (Jeninga et al. 2009). Depending on the ethnic group, 
the frequency of this most common replicated single nucleotide polymorphism 
(SNP) in diabetes varies between 2-25% (Jeninga et al. 2009; Ridderstråle & 
Groop, 2009). 
 
b. Inflammation and obesity  
Obesity, mainly visceral adiposity, a main element in insulin resistance 
process, is associated with an inflammatory response. An increase in adipose 
tissues, caused by hypertrophy and hyperplasia of adipocytes, results in a decrease 
in the oxygen supply vs demand, causing cell hypoxia of adipocytes thus 
launching an inflammatory pathway. This process involves recruitment of 
macrophages and the secretion of cytokines such as interleukin-6 (IL-6), IL-8 and 
Tumour necrosis factor α (TNFα) (Luca & Olefsky, 2007; Giorgino et al. 2005); 
the latter being the main pro inflammatory cytokine involved in insulin resistance 
related to obesity (Mlinar et al. 2007). 
The large amounts of TNFα released from the adipose tissues, provoke the 
secretion of FFA in the circulation, the excess of which will affect the different 
organs that constitute the target territory where insulin performs its functions 
(Mlinar et al. 2007). 
In the muscles, elevated levels of FFA, foster beta oxidation that in turns, 
results in diminishing glucose oxidation and uptake, and inhibit glycogen 
synthesis (Mlinar et al. 2007). In the adipose tissues, they reduce the lipoprotein 
lipase activity, preventing the disposing of FFA from the blood. In the liver, 
gluconeogenesis takes place simultaneously with the synthesis of triglycerides and 
very low density lipoproteins (VLDL) from FFA (Mlinar et al. 2007). 
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 Figure 2: The effect of obesity on different organs and the development of insulin 
resistance (Luca & Olefsky, Inflammation and insulin resistance. Federation 
of European Biochemical Societies. 2007; 582: 97-105). 
 
 
1.2.2. Pancreatic β cell failure  
β cell failure that leads to a progressive decrease in insulin secretion is the result 
of environmental and genetic factors. The main underlying reason is the apoptosis 
of β cells that causes a reduction in β cell mass. This is caused by glucotoxicity, 
where the chronic elevation of glucose level increases the apoptosis rate of β cells 
through the generation of reactive oxygen species (ROS) (Lupi & Prato, 2008). 
Also by lipotoxicity due to the high levels of FFA in the blood and their 
generation of Nitric oxide and by an increase in amyloid deposition in the 
pancreatic β cells, considered to be toxic for these cells (Lupi & Prato, 2008). 
 
a. Genetic elements 
Several genes such as Transcription factor-7-like 2, TCFL2, and solute 
carrier family 30 member 8, SLC30A8, have been identified to have an effect on β 
cell functions. 
Transcription factor-7-like 2, TCFL2 gene, is one of the first susceptibility 
genes for T2D to be replicated by GWAS (Doria et al. 2008). It is located on 
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chromosome 10q25 and is involved in WNT signaling pathways as the β catenin 
nuclear receptor. This pathway is essential for embryogenesis and pancreatic Islet 
cell development (Ridderstråle & Groop, 2009 ; Doria et al. 2008). The binding of 
TCFL2 to the β catenin nuclear receptor causes the transcription of several genes 
such as intestinal proglucagon, glucagon like peptide-1 (GLP-1) and glucagon like 
peptide -2 (GLP-2) (Ridderstråle & Groop, 2009) responsible for the regulation of 
glucose homeostasis. The rs7903146 in TCFL2 with T as the risk allele is linked 
to diabetes (Owen et al, 2007). The mutation in TCFL2 gene inhibit the positive 
stimulatory effect of both GLP-1 and 2 on insulin, causing a decrease in insulin 
secretion from pancreatic β cells (Ridderstråle & Groop, 2009). In different ethnic 
groups, carriers of the risk allele have a 30%-50% increased risk to develop T2D 
(Hattersley,  2007). 
SCL30A8, solute carrier family 30 member 8 gene, located on chromosome 
8q24.11, is a member of the Zinc transporter family (Xu et al. 2010).  The gene is 
formed of eight exons and codes for a 369 amino acid protein, known as the Zinc 
transporter-8 (ZnT8) (Xu et al. 2010). This transporter has a major role in Zinc 
transport from the cytoplasm into the insulin vesicles of the nuclei of pancreatic 
islets cells (Xu et al. 2010). The zinc is essential for insulin maturation from 
proinsulin to insulin, storage and secretion (Xu et al. 2010). A missense mutation, 
rs1326634 C/T, altering arginine to tryptophan at position 325 (R325W), is 
implicated in T2D, by affecting  zinc transfer (Xu et al. 2010; Doria et al. 2008). 
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Figure 3: A display of all the factors involved in T2D pathogenesis (Jin & Patti, 
Genetic determinants and molecular pathways in the pathogenesis of type 2 
diabetes. Clinical Science. 2009. 116, 99-111). 
 
1.3. Approaches in gene discovery 
From spring 2010, more than 40 different loci have been linked to T2D (Walford 
& Florez, 2010). Initial studies were made possible through linkage analysis that 
identified monogenic forms of diabetes such as Maturity onset diabetes of the young 
(MODY), neonatal diabetes, both representing 2-5% of diabetic cases (Majithia & 
Florez, 2009). That was then followed by the candidate gene scheme used to detect 
mutations in genes known to have a role in the pathophysiology of the disease (Walford 
& Florez, 2010). Recently, these two methods were complemented by GWAS. GWAS 
was made possible after the sequencing of the human genome, and it allowed the 
detection of SNP in genes with no prior biological knowledge of these specific genes 
(Grarup, Sparso & Hansen, 2010). 
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1.4. Functions of the new genes 
All the genes identified and proved to be associated with diabetes represent less 
than 10% of T2D genetics. Three new SNP have been identified recently and are 
considered to be positioned near candidate genes involved in this disease pathogenesis 
(Voight et al., 2010). These SNP, rs7957197, rs1531343, rs972283, not previously 
related to T2D, are located near the genes Hepatocyte Nuclear Factor 1 A (HNF1A), 
High Mobility Group A2 (HMGA2) and Krupel-like factor 14 (KLF14) respectively, 
and represent the core of this thesis. Hence a description of the nearby genes looks to be 
an indispensable step in discovering new pathways for T2D pathogenesis. 
 
1.4.1. Hepatocyte Nuclear Factor 1 A (HNF1A) 
HNF1-A, a transcription factor responsible for the genes regulation in the liver, 
kidneys and pancreas, is located on chromosome 12q24.2 and is formed of 10 exons 
(Ryffel, 2001). Its structure is composed of three functional domains: a dimerization 
domain at the N-terminal, a DNA binding domain from amino acid 100 till amino acid 
281 and a transactivation domain at the C-terminal (Chantelot et al. 2008). HNF1-A 
binds a conserved sequence, GTTAATTNATTANC constituted of 13 bases located in 
the promoter segment of the target genes (Ryffel, 2001). In the liver, it controls genes 
whose products are involved in lipid, carbohydrate metabolism, seroproteins synthesis 
and in detoxification such as apolipoproteins, aldolase, albumin, and cytochromes 
respectively (Cereghini, 1996; Fajans, Bell & Polosky, 2001). In the kidneys, HNF1-A 
affects the sodium dependent glucose transporter 2 (SGLT2), located in the tubular cells 
(Ryffel, 2001). Accordingly, a mutation in HNF1-α will cause a decrease in glucose 
reabsorption at the level of proximal tubules resulting in glucosuria (Ryffel, 2001). In 
the pancreas, HNF1-A regulates the genes coding for insulin, glucose transporter 2 
(GLUT 2), pyruvate kinase and more (Pontoglio, 2000), all crucial for the β cells 
secretory and metabolic functions (Ryffel, 2001). 
Moreover, a mutation in this gene is associated with the Maturity onset diabetes 
of the young type 3 (MODY 3), characterized by a deficit in insulin secretion and a 
decrease in renal glucose reabsorption (Fajans et al. 2001). More than 200 mutations, 
classified either as missense or insertion/deletion mutations, have been identified in 
HNF1-α and linked to MODY 3 (Chantelot et al. 2008).    
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But recently, it has been proven that a mutation in HNF1-α gene is related to 
T2D. It is attributed to a very common polymorphism, the substitution of isoleucine to 
leucine (I27L) located in exon 1, in the dimerization domain of the gene. This mutation 
induces a small conformational change and affects the DNA binding capacity of the 
gene. Due to this substitution, the transcriptional activity of the GLUT 2 gene is reduced 
(Chen et al. 2010). Thus, less glucose will be transported into the β cells, and ultimately 
less insulin will be secreted (Fajans et al. 2001). So I27L causes a dysfunction in β cells, 
influencing insulin secretion and thus increasing the risk of T2D (Chen et al. 2010). 
Therefore, unrelated mutations on HNF1-α gene may either cause a monogenic form of 
diabetes or induce the most common form of diabetes, T2D (Chiu, Chuang, Chu, Yoon 
& Wang, 2003). 
Furthermore, mutations in HNF1α gene are related to the C- reactive protein 
(CRP) concentration in the plasma (Reiner et al. 2008). This inflammatory protein is 
mainly produced by liver cells and its transcription is controlled by IL-6, IL1-β and NF-
κB (Reiner et al. 2008). HNF1-A binds to the promoter of the CRP gene at the same 
binding site of NF-κB gene (Reiner et al. 2008). So, HNF1-A can regulate CRP 
synthesis by the liver (Reiner et al. 2008).  One common SNP is the Rs1169310 (G/A), 
located in the 3’UTR region of HNF1α and has the strongest association with CRP 
levels in the blood (Reiner et al. 2008).  
The SNP rs7957197, considered a new polymorphism associated with T2D is 
located on chromosome 12q24.3, in the intron region of the gene 2’-5’- oligoadenylate 
synthetase-like (OASL) and has T allele as its risk allele (NCBI). 
 
1.4.2. High Mobility Group A2 (HMGA2) 
HMGA2, a DNA binding protein, is a member of the High mobility group 
family A (HMGA) (Fedele & Fusco, 2010). The gene is located on chromosome 12q14, 
and spans a region on the DNA of at least 160 Kb (Ashar, Tkachenko, Shah & Chada,  
2003).  It is a nuclear protein, with a mass of less than 30 KDa and implicated in 
chromatin structural changes and in gene transcription regulation (Bianchi & Agrsti, 
2010; Fedele & Fusco, 2010). This gene is formed of three DNA binding domains at the 
N terminal, known as AT-hooks able to bind to target DNA segment rich in AT 
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sequences, and of an acidic C terminal essential for protein-protein interactions (Ashar 
et al. 2003).  
In 2006, Hock, Furusawa, Ueda and Michael proved that mice over expressing a 
truncated form of hmga2 lacking the C tail, are obese and giant (Hock et al. 2006). Thus 
HMGA2 has a role in obesity and in height regulation. Anand and Chada proved that in 
hmga2−/− null mice, no difference was detected in weight gain when mice were fed 
with either normal or high fat diet. Accordingly it is the deletion in hmga2 allele that 
prevented the mice from gaining weight (Anand & Chada , 2000). 
Additionally, HMGA2 regulates insulin-like growth factor binding protein 2 
(IGFBP2) which encodes a protein that binds to the 5’UTR region of the insulin growth 
factor 2 (IGF2), essential for insulin signaling (Rodriguez et al. 2010). IGFBP2 
mutation, rs4402960, influence β cell functions and causes a decrease in insulin 
secretion (Rodriguez et al. 2010).The mechanism through which IGFBP2 affects these β 
cells is unknown. It may be that IGFBP2 causes the sequestration of IGF2 mRNA in β 
cells, ending up in a decrease in β cells volume and in insulin secretion (Cleynen et al. 
2010). 
Furthermore, the rs4409260 mutation identified in IGFBP2, is positioned within 
a long haplotype block with isofrequent alleles that spans most of intron 1 and intron 2 
of the gene (Rodriguez et al. 2010). And knowing that HMGA2 binds to the AT rich 
region of IGFBP2 present in the first intron of the gene, it is possible that HMGA2 
regulates the alleles of rs4409260, inducing a modification in the function of IGFBP2 
and eventually in the expression of IGF2 (Rodriguez et al. 2010). 
As already mentioned, and in addition to its involvement inT2D pathogenesis, 
HMGA2 gene regulates height, especially childhood height. The two SNP identified in 
the gene are rs1042725 and rs7968682 and are located within and 12 Kb downstream of 
the 3’UTR segment of the gene respectively (Weedon et al. 2007). With no influence on 
the birth height, rs1042725 (T/C) affect childhood height from the age of 7 till 11 years, 
increasing limb length by 0.3 cm and sitting height by 0.2 cm with each C allele 
(Weedon et al. 2007). 
Rs1531343, the SNP of interest, is located on chromosome 12q15 and has C 
allele as its risk allele (NCBI). 
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1.4.3. Krupel-like Factor 14 (KLF14) 
KLF14, located on chromosome 7q32.3, belongs to the KLF family. This group 
is constituted of 17 members that regulate cellular proliferation, differentiation and 
apoptosis (Rodriguez & Martignetti, 2009). Each of the KLF has a distinct function, but 
they all share a conserved structure. At the N-terminal, is located a variable segment 
that regulates the transcription of genes. At the C-terminal, three cysteine2/histidine2 
with zinc fingers constitute the DNA binding segment (Rodriguez & Martignetti, 2009). 
The zinc fingers are separated by five amino acid residues, TGEKP, conserved among 
all KLF families (Haldar, Ibrahim & Jain, 2007). These transcription regulator proteins, 
through their C2H2 zinc fingers, are able to bind to specific sequences such as CACC or 
GC-GT elements, located in the promoter region of their target gene (Aguilar et al. 
2007). 
In 2009, Truty et al, in their work on pancreatic cancer cells, identified the first 
function of KLF14, as being the repressor of the transforming growth factor β receptor 
II gene (TGFβRII)  (Truty, Lomberk, Zapico & Urrutia, 2009). 
This TGFβRII belongs to the transforming growth factor β (TGFβ) signaling 
pathway. This pathway regulates a number of cellular activities, including cell 
differentiation, proliferation and apoptosis, with a negative influence on cellular growth 
(Shi, Massague & Thoma, 2003). The TGFβ ligands such as TGFβ cytokines and the 
Anti-Mullerian hormone, bind to the TGFBRII inducing the phosphorylation of the 
serine residues of the transforming growth factor β receptor I (TGFβRI) and 
transmitting the signal through the phosphorylation of intracellular SMAD proteins. The 
latter are transcription regulators elements. And once these proteins are phosphorylated, 
they are transferred to the nucleus where they regulate the transcription of the gene of 
interest by binding to the GTCT sequence located in the promoter region of the gene 
(Shi et al. 2003). 
During the period of development, the TGFβIR and TGFβIIR are located in the 
pancreatic epithelium, and later in the pancreatic islets and ducts (Lin et al. 2009). Also, 
the regulatory SMAD proteins are present in the pancreas (Lin et al. 2009). Thus, the 
TGFβ signaling pathway is involved in pancreatic diseases (Lin et al. 2009). Such as the 
SMAD 3 proteins suppresses the insulin gene through their binding to the gene 
promoter, and thus inhibition of the smad3 signal will cause an increase in insulin 
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secretion (Lin et al. 2009). As well, an over activation of the TGFβ pathway will repress 
the genes needed for insulin synthesis and glucose metabolism (Lin et al. 2009). 
Truty et al. (2009) proved that KLF14 limits the activity of TGFβRII through a 
negative feedback loop. The binding of the TGFβ ligands, such as TGFβ1 to the TGβRI, 
activates the TGFβ pathway and causes the expression of KLF14 (Truty et al. 2009). 
Once up-regulated, KLF14 binds to the GC rich sites in promoter region of TGFβRII 
and competes with SP1. And through its hydrophobic sequence in N-terminal segment, 
KLF14 binds to Sin3a. The latter is a co-repressor molecule that suppresses the target 
gene through its interaction with transcription factors such as the KLF and Histone 
Deacetylases (HDAC) (Truty et al. 2009). All these events will cause a chromatin 
remoldeling of the TGFβRII gene, converting the active to an inactive form of the gene 
(Truty et al. 2009). 
To mention, that SP1 belongs to the SP/KLF family. This group is composed of 
specificity protein 1 to 4 (SP1-4) sharing the same structure as the other KLF members 
(Truty et al. 2009).They are involved in regulating signal transduction pathway and 
considered recently as non-SMAD regulator of TGFβ pathway (Truty et al. 2009).  
As for the SNP of the study, rs972283 of KLF14 is located on chromosome 7q32 
and has C as its risk allele (NCBI). 
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Figure 4: The mechanism for the Downregulation of TGFβRII gene by the KLF14. 
(Truty et al. Silencing of the Transforming Growth Factor-β (TGFβ) 
Receptor II by Kruppel-like Factor 14 Underscores the Importance of a 
Negative Feedback Mechanism in TGFβ Signaling.  The Journal of 
Biological Chemistry. 2009. 284, 6291-6300). 
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CHAPTER 2 
MATERIALS AND METHODS 
 
2.1. Profile of the study group 
640 non diabetic above 60 years of age and 565 Diabetic, all unrelated Lebanese, 
previously included in the cardiac study of the Genomic laboratory, represented the 
population of my study. Controls were defined as having no diagnosis of diabetes, and 
cases are individuals with a reported diagnosis of T2D. All participants answered a 
questionnaire a propos of the age, diabetic status, anti-diabetic medication and relevant 
clinical information such as BMI value, cholesterol level and family history. All 
subjects, following clinical indication, had a cardiac catheterization performed in Rafic 
Hariri University Hospital or the American University of Beirut Medical center. 
The DNA was extracted from 10 ml of blood previously drawn from each subject 
and stored at 4°C. 
 
2.2. SNP selection 
The SNP rs972283, rs1531343, rs7957197, represent the target of the current 
study; their specifications according to the TaqMan® SNP Genotyping Assays by 
Applied biosystems are illustrated in the following table: 
Assay ID NCBI SNP Reference Nearby gene Chromosome Mutation 
C___7614445_10 rs972283 KLF14       7 A/G 
C___1692218_10 rs1531343 HMGA2       12 G/C 
C__29094181_10 rs7957197 HNF1-A       12 A/T 
 
Table 1: Specifications of the SNP of interest 
 
 
2.3. SNP Genotyping 
The technique used in this experiment is the Applied biosystem 7900 HT fast real 
time PCR system. 
40× SNP aliquots were diluted to a 20×working stock solution with a 1×TE buffer 
of 10 mM Tris-HCl, 1 mM EDTA, and a pH of 8.0. 
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The stock DNA was diluted with DNase-free water and 10 ng of the diluted DNA 
was used for each of the TaqMan SNP genotyping assays. The latter reaction requires a 
DNA concentration ranging from 1 to 20 ng.  
The 20µL PCR amplification reaction is formed as well of 9.2µL of 1×TaqMan 
universal PCR Master Mix, 0.8µL of 20×SNP genotyping assays that included the 
forward and reverse primers to amplify the sequence of interest, and two TaqMan minor 
groove probes to differentiate between the risk and the non risk alleles (TaqMan® SNP 
Genotyping Assays, Protocol, Applied Biosystems). 
The TaqMan probe is a fluorogenic probe, complementary to the target sequence 
and has a reporter dye at the 5’end (VIC dye linked to allele 1 of the probe, FAM dye 
linked to allele 2 of the probe) and a quencher at the 3’end. The proximity between the 
reporter and the quencher prevents the emission of fluorescence from the reporter 
TaqMan SNP Genotyping Assays Protocol. Applied Biosystems). 
 
 
Figure 5: TaqMan probe. Presence of a reporter at the 5’ end and of a Quencher at the 
3’ end (Real Time PCR: The TaqMan Method. Pierce, 2003) 
 
2.4. Steps of the Real time PCR reaction 
During PCR reaction, the TaqMan probe and the primers bind to the target DNA 
sequence. The Taq polymerase adds nucleotide to extend the primers and replicates the 
DNA strand to which the probe is attached. The 5’exonuclease activity of the enzyme 
cleaves the probe, separating the Quencher and the Reporter, resulting in the release of 
fluorescence by the reporter dye (TaqMan SNP Genotyping Assays Protocol. Applied 
Biosystems). 
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Figure 6: Steps of the Real Time PCR reaction in SNP Genotyping (TaqMan SNP 
Genotyping Assays Protocol. Applied Biosystems. 2006) 
 
 
 
 
 
The conditions for the PCR reaction are illustrated in Table 2 (TaqMan SNP Genotyping 
Assays Protocol . Applied Biosystems). 
 
Table 2: Settings for the PCR reaction 
  
AmpliTaq Gold enzyme activation 95°C for 10 min 
  
Denaturation 45 cycles of 95°C for 15 sec 
Annealing and extension 45 cycles of 60°C for 1 min 
  
 
Subsequent to PCR amplification, an endpoint plate read using the 7900HT fast real 
time PCR system measures the fluorescence in each well. The Sequence Detection System 
Software plot the values of the measured fluorescence, and determines the alleles 
identified in each well (TaqMan SNP Genotyping Assays Protocol. Applied Biosystems).The 
results were reconfirmed manually as well. 
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2.5. Statistical analysis 
Chi-square test was used to compare discrete variables, allele and genotype 
frequencies between cases and controls. The Student’s t-test was used to compare 
continuous variables expressed as means +/- standard deviation. Odds ratio (OR) with 
95% confidence interval (CI) were calculated to evaluate the strength of association 
between the calculated alleles or genotypes frequencies and the clinical data. A two 
tailed p value of less than 0.05 was considered statistically significant and an Odds ratio 
of more than 1 was taken as a positive risk.  
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CHAPTER 3 
RESULTS 
 
3.1.  Features of studied population 
The diabetic status was the main criterion used to classify the population as cases 
or controls. A comparison was made, presented in Table 3, for variables considered as 
risk factors for T2D between the diabetic and the non diabetic population. The mean age 
of the study group was lower (P = 0.0001) than the control group due to the fact that all 
subjects of the latter group were aged more than 60 years. The calculated percentages of 
females and of subjects with a positive family history were higher in the cases as 
compared to the controls with p values of 0.04 and < 0.0001 respectively.  
Glucose level and the body mass index (BMI) of the diabetic group were 
significantly higher than those of the control group (P = 0.0001 in both conditions). No 
significant differences were detected in the total cholesterol, High density lipoproteins 
(HDL), Low density lipoproteins (LDL) and Triglycerides of the 2 groups, with p 
values of 0.33, 0.46, 0.21 and 0.09 respectively. However, the percentage of subjects 
diagnosed as lipidemic was significantly higher in the cases than in the controls (P < 
0.0003).  
 
Table 3: Characteristics of the studied population (N=1208). 
 
  Diabetic Non Diabetic  P -values 
  N = 565 N = 643 
 Age (years) 62  ±  9.78 70 ± 6.82 0.0001 
Female (%) 40 34 0.04 
Family history of diabetes (%) 68 33.20  <0.0001 
BMI (Kg/m2) 30.22  ± 5.77 28.58     ±  4.84 0.0001 
Glucose (mg/ dl) 177  ±   100  112.22  ±  30.44 0.0001 
Lipidemic (%) 57 42 < 0.0003 
Total cholesterol (mg/ dl) 202 ± 131 195.39  ±  104.88 0.33 
HDL (mg/ dl) 61   ±  143 55.60  ±  111.29 0.46 
LDL (mg/ dl) 150  ± 176  138.35  ±  149.06 0.21 
Triglycerides (mg/ dl) 409  ±  1446 284.33  ±  1142.06 0.09 
 
All means compared by student-t-test 
Percentages compared by chi-square test 
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3.2. The Genotype and Allele frequencies of Diabetic Vs Non Diabetic subjects  
The three SNP mentioned above were genotyped and compared between both 
groups of diabetic and controls. The results did not reveal any significant difference for 
the genotype and allele frequencies for both of KLF14-rs972283 and HMGA2-
rs1531343 with a p value of more than 0.05 for both SNP (P = 0.27 and 0.58 
respectively) (Table 4). Whereas for HNF1A-rs7957197, the diabetic population 
showed a higher frequency of TT genotype  
(P = 0.02) with OR: 2.92 (1.23-6.66) 
 
Table 4: Genotype and allele frequencies for HMGA2-rs1531343, HNF1A-
rs7957197 and KLF14-rs972283 in diabetic and in control subjects. 
 
  
 Non 
Diabetic  Diabetic       P value 
rs1531343       
GG 380 350 
 CC 33 25 0.27 
GC 210 159 
 G 970 859 0.12 
C 276 209   
    
rs7957197       
AA 335 315 
 TT 8 22 0.02 
TA 147 144 
 A 817 774 0.09 
T 163 188   
    
rs972283       
AA 112 128 
 GG 45 41 0.58 
GA 123 144 
 A 347 400 0.49 
G 213 226   
 
3.3. The Genotype and Allele frequencies of Female Diabetic Vs Male Diabetic 
subjects  
The diabetic population was subdivided into males and females. The data analysis 
of this group showed no significant differences between both genders, corresponding to 
the three SNP, with a P value > 0.05 in all cases (Table 5). 
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Table 5: Genotype and allele frequencies for HMGA2-rs1531343, HNF1A-rs7957197 
and KLF14-rs972283 in Female diabetic and in Male diabetic subjects. 
 
                  Diabetic   
 
Female Male P value 
rs1531343       
GG 135 215 
 CC 10 15 0.81 
GC 66 93 
 G 336 523 0.58 
C 86 123   
    
rs7957197       
AA 124 191 
 TT 6 16 0.5 
TA 58 86 
 A 306 468 0.56 
T 70 118   
    
rs972283       
AA 54 74 
 GG 19 22 0.53 
GA 54 90 
 A 162 238 0.95 
G 92 134   
 
3.4. The Genotype and Allele frequencies of Diabetic with a positive or negative 
Family history for T2D 
A comparative study, of the positive T2D family history and the negative T2D family 
history subjects that constitute the diabetic group, proved no discrepancy between the genotype 
and allele frequencies of the three SNP, HMGA2-rs1531343, HNF1A-rs7957197 and 
KLF14-rs972283 with P values of 0.39, 0.36 and 0.72 respectively. (Table 6)     
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Table 6: Genotype and allele frequencies for HMGA2-rs1531343, HNF1A-rs7957197 
and KLF14-rs972283, in diabetic with a positive or negative family history for 
T2D. 
 
                            Diabetic     
 
No  Family History Positive Family History     P value 
rs1531343       
GG 105 241 
 CC 10 13 0.39 
GC 52 107 
 G 262 589 0.23 
C 72 133   
    
rs7957197       
AA 106 205 
 TT 9 13 0.36 
TA 41 102 
 A 253 512 0.69 
T 59 128   
    
rs972283       
AA 40 86 
 GG 12 28 0.72 
GA 39 104 
 A 119 276 0.62 
G 63 160   
 
3.5. The Genotype and Allele frequencies of Diabetic with BMI < 30 AND BMI ≥ 
30                
Considering obesity as a main risk factor for T2D, genotype and allele frequencies were 
calculated for the three polymorphisms. No positive association was detected between these 
mutations and BMI values. The P value was more than 0.05 in the three cases (Table 7). 
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Table 7: Genotype and allele frequencies for HMGA2-rs1531343, HNF1A-rs7957197 
and KLF14-rs972283 in diabetic with BMI less or more than 30  
 
    Diabetic   
 
BMI < 30 BMI  ≥ 30       P value 
rs1531343 
   GG 166 159 
 CC 15 10 0.25 
GC 89 63 
 G 421 381 0.1 
C 119 83   
    
rs7957197       
AA 162 133 
 TT 13 8 0.51 
TA 68 67 
 A 392 333 0.81 
T 94 83   
    
rs972283       
AA 63 59 
 GG 19 18 0.94 
GA 65 66 
 A 191 184 0.87 
G 103 102   
 
3.6. The Genotype and Allele frequencies of Diabetic with respect to the 
treatment with either insulin or with Oral hypoglycemic agents (OHA) 
When accounting for the protocols used to manage and control diabetes, and when 
evaluating A vs. T being the risk allele, rs7957197 revealed significant variation in the 
allele frequencies between diabetic patients treated with any OHA and patients treated 
with insulin. Patients of the former group were found to have a higher T allele (P = 
0.03) than diabetic patients treated with insulin (Table 8).  
A noteworthy finding (P = 0.04) was noticed in allele frequencies of rs7957197, 
among subjects not under insulin injections therapy. These patients were found to have 
a higher T allele, in contradistinction with subjects treated with insulin injections (Table 
9). 
With regards to the rs972283 polymorphism, significant differences (P = 0.02) in 
genotype frequencies were identified among patients under insulin and patients 
following different strategies of treatment (Table 9). An association was found between 
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no need for insulin injections in treatment and the GG genotype of the KLF14-
rs972283. 
 
Table 8: Genotype and allele frequencies for HMGA2-rs1531343, HNF1A-rs7957197 
and KLF14-rs972283 in diabetic with respect to treatment.  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9: Genotype and allele frequencies for HMGA2-rs1531343, HNF1A-rs7957197 
and KLF14-rs972283 in diabetic under insulin therapy or treated differently.  
    
                  Diabetic   
 
OHA Insulin P value 
rs1531343       
GG 160 31 
 CC 8 3 0.31 
GC 75 22 
 G 395 84 0.13 
C 91 28   
    
rs7957197       
AA 148 25 
 TT 8 5 0.06 
TA 66 16 
 A 362 66 0.03 
T 82 26   
    
rs972283       
AA 53 11 
 
GG 19 
 
3 0.86 
GA 71 16 
 A 177 38 0.83 
G 109 22   
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                  Diabetic   
 
Insulin no insulin       P value 
rs1531343       
GG 31 219 
 CC 3 17 0.32 
GC 22 99 
 G 84 537 0.21 
C 28 133   
    
rs7957197       
AA 25 202 
 TT 5 12        0.08 
TA 16 95 
 A 66 499        0.04 
T 26 119   
    
rs972283       
AA 11 82 
 GG 3 27 0.02 
GA 16 93 
 A 38 257 0.96 
G 22 147   
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                                              CHAPTER 4 
DISCUSSION 
  
The continuous identification of new susceptibility genes associated to T2D 
appears to be an active process and remains a vital challenge; it is considered to be the 
only route to elucidate the complex pathogenesis underlying the development of the 
T2D. The latter is a polygenic, complex disease, caused by a combination of a genetic 
predisposition and environmental factors; positive family history, obesity and physical 
inactivity are considered essential risk factors for this disease.  
The goal of this study is to identify the polymorphisms, rs7957197 in HNF1A, 
rs1531343 in HMGA2 and rs972283 in KLF14 in the Lebanese diabetic population with 
an emphasis to discover a correlation of these mutations with the risk factors and 
treatment of T2D.  
Our group of study was divided between controls, selected as subjects with no 
known history of T2D, and cases chosen as individuals with a confirmed diagnosis of 
T2D. 
The TT genotype of rs7957197 in HNF1A, with T as the risk allele, is associated 
to T2D in the Lebanese population (P = 0.028). But the genotype and allele frequencies 
of rs1531343 in HMGA2 and rs972283 in KLF14 did not show a significant difference 
when comparing between nondiabetic and diabetic subjects. 
Voight et al. (2010), did establish an association between these three SNP and 
T2D, in 34,412 cases and 59,925 controls, all of European descent, from Germany, UK, 
Italy and other countries (Voight et al. 2010). But in their study, they performed a meta-
analysis of eight GWA of T2D to identify common polymorphisms of weak impact 
associated with this disease.  In addition to their larger sample size, they did genotype 
2,426,886 SNP, thus amplifying the probability to detect any polymorphism linked to 
T2D. They were able to identify 12 new SNP, out of which only HNF1A, HMGA2, 
KLF14, were considered to be essential candidate genes that increase the susceptibility 
to T2D. 
Also, the non replication of two of these SNP in the Lebanese diabetic population 
is caused by several factors. First, allele frequencies vary within the same population 
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and between different populations (Cardon & Palmer, 2003). As well, gene-
environment interactions, genetic and environmental heterogeneity between populations 
represent the main reasons behind the lack of reproducibility between studies (Cardon & 
Palmer, 2003).  Other potential risk factors responsible for the irreproducibility of 
results are population stratification and publication of only positive findings (Cardon & 
Palmer, 2003). 
Regarding the studied population, the diabetic group did have a higher occurrence 
of a positive ancestry for T2D, and higher means for BMI and blood glucose level 
(Table 3). Based on the available records, and on the lack of comprehensive data 
regarding the lipid profile for all studied subjects, no significant differences were 
detected regarding the total cholesterol, LDL, HDL and triglycerides, between the cases 
and controls. However, a significant dissimilarity was detected when comparing 
between the percentages of diabetic lipidemic and non diabetic lipidemic. 
Dyslipidemia in diabetic patients is characterized by high plasma triglycerides, a 
low HDL and a high LDL levels in the blood (Mooradian, 2009). These features of 
dyslipidemia are related to the insulin resistance of T2D, with the main cause being the 
high levels of circulating FFA (Mooradian, 2009). The Framingham Heart Study did 
reveal that 19% of diabetic males and 17% of diabetic women have elevated 
concentrations of triglycerides as compared to 9% and 8% of non diabetic men and 
women respectively. Yet, diabetics from both genders have similar total cholesterol and 
LDL concentrations as non diabetic men and women (Mooradian, 2009). Furthermore, 
the frequency of low HDL was much more common in diabetic men and women (21% 
and 25% respectively) as compared to non diabetic males and females (12% and 10% 
respectively) (Mooradian, 2009). 
The frequency of dyslipidemia is not increased in diabetic patients, but when 
present, it adversely affects the mortality rate from cardiovascular conditions 
(Mooradian, 2009). But our results indicated a higher percentage of diagnosed lipidemic 
in cases than controls. 
As for the gender, no significant statistical differences (P > 0.05) were detected 
between diabetic males and females for rs7957197 in HNF1A, rs1531343 in HMGA2 
and rs972283 in KLF14. It is documented that the incidence of T2D is almost similar 
between males and females (Franconi et al. 2008). But, diabetic females unlike diabetic 
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males, have an isolated postprandial hyperglycemia rather than a fasting hyperglycemia 
(Franconi et al. 2008). So a proper diagnosis of T2D in females based on fasting 
hyperglycemia can cause an “under-diagnosis” of diabetic females (Franconi et al. 
2008).  
However, differences between the two genders are detected in the associated 
cardiovascular conditions. Diabetic females have a 4-6 fold increase in the risk to 
experience a coronary artery disease compared to a 2-3 fold increase for diabetic male 
(Legato et al. 2006). Also, diabetic females have a 50% higher chance to suffer from a 
fatal heart attack (Franconi et al. 2008). 
 
Furthermore, despite the fact that a positive family history of T2D is the foremost 
risk factor for the disease development, no significant divergence was observed when 
the population of our work was subdivided according to the presence or absence of a 
family history of T2D (P  > 0.05 in the three mutations).  
An African study revealed that individuals with a positive family history of T2D 
have higher levels of blood glucose and a 4 fold increased risk to develop diabetes 
(Bochud et al. 2004). Furthermore, Bochud et al. (2004) studied the analytical validity, 
sensitivity and specificity of the component of the family history of T2D, considered to 
be an essential element used in screening projects that aim to detect the incidence of a 
particular disease in a family. The sensitivity represented the rate of individuals who 
reported the presence of disease in truly affected siblings, whereas specificity 
constituted the proportion of subjects who reported the absence of the disease in really 
unaffected siblings . Consequently, it was established that the sibling history of diabetes 
had a low sensitivity (53.4%) and a high specificity (98.2%). Hence, these results reveal 
that the family history of diabetes is a weak screening tool to forecast diabetes in 
siblings. 
In the population of our work, 93% of diabetic subjects had a sibling or parent 
with the disease, 5% had diabetic cousins or aunts, and the rest had grandparents with 
the disease. But such data, despite the high specificity as mentioned earlier, does not 
reflect the true T2D heritability with regards to the link between the family history and 
the mutations of rs7957197 in HNF1A, rs1531343 in HMGA2 and rs972283 in KLF14.  
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Moreover, considering the analysis done based on BMI, the allele and genotype 
distributions of the three polymorphisms, did not prove any significant association 
between obesity, a BMI >30, with the higher risk to develop T2D (P > 0.05 for all three 
SNP), despite the fact that deletion of HMGA2 was proven to be associated with obesity 
in mice (Anand & chada,  2000). 
This finding is also supported by the study done by Voight et al. (2010). Their 
sample volume consisted of 21,000 individuals, but still, they did not detect a new gene 
that may link obesity to T2D. Accordingly so far, the only gene with its risk allele 
related with obesity and T2D is the fat mass– and obesity associated gene (FTO) the 
variations of which accentuate the risk for both of the diseases. One common 
polymorphism, the A allele of rs9939609, where each copy of this risk allele, increases 
BMI by 0.4 kg/m2, and a 1.31 folds higher odds of obesity and  higher chances of T2D, 
1.25 higher odds for each allele (Freathy et al. 2008). 
In the same context, no information is available to elucidate the impact of the 
probable differences in BMI values that may be observed between the time when the 
diagnosis was done and the time of our study. 
In addition, the treatment options of T2D target the two main defects in the 
pathogenesis of the disease. As mentioned earlier, the initial phase of the disease is 
characterized by an insulin resistance, compensated by an increase in insulin secretion 
by pancreatic β cells. Later, these cells will become dysfunctional and will limit their 
secretion of insulin. Both of these conditions lead to hyperglycemia (Bailey, 2000).  
The treatment options include insulin injections or different classes of oral 
hypoglycemic agents (Bailey, 2000). The latter, such as Thiazolidinediones, increase the 
insulin action through its influence on the insulin resistance that will subsequently cause 
a decrease in fasting and postprandial glucose. On the other hand, sulfonylureas 
contribution to diabetes management is materialized by directly stimulating the pancreas 
to produce and secrete more insulin (Bailey, 2000). 
Following an expected decrease in pancreatic β cell functions, these oral 
medications fail to adequately regulate the plasma glucose level; at this point, insulin 
injections are introduced as a complementary element to the treatment protocol (Bailey, 
2000). These injections will elevate plasma insulin level, and that amplifies the 
peripheral glucose utilization (Bailey, 2000).   
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In this study, the treatment option with either insulin injections or an oral 
hypoglycemic agents was used to sub classify the diabetic subjects. The risk allele T of 
rs7957197-HNF1A, was proven to be more frequent in diabetic individuals treated with 
OHA as compared to either insulin treatment (P = 0.03) or to a treatment without insulin 
(P = 0.02). Similarly, the genotype GG of KLF14-rs972283 was found to be linked to 
diabetic patient not treated with insulin (P = 0.02). This may suggest that both of these 
mutations may be protective against a severe β cell failure, since these diabetic patients 
were still able to control the glucose level in the plasma with oral agents only. 
However, our results do not contradict the finding obtained with Voight et al. 
(2010) for KLF14 only. In the latter study, they evaluated the activity of β cell function 
and insulin resistance through the measurement of the Homeostasis model assessment 
of β cell function (HOMA-β) and the Homeostasis model assessment of insulin 
resistance (HOMA-IR) respectively. They proved that only KLF14 is associated with a 
higher insulin resistance  
(p < 0.05) and no significant correlations were identified for HNF1-A and HMGA2 . 
Also, the fasting insulin levels were measured in order to further determine 
whether these mutations are linked to pancreatic β cell failure or to insulin resistance. 
They detected an elevated fasting insulin level, in rs972283-KLF14, (P = 0.029), 
implying that this mutation was without a doubt associated with a defect in insulin 
action at the level of the tissues and not in insulin secretion (Voight et al. 2010). As for 
rs7957197-HNF1A and for HMGA-2, the fasting insulin levels were measured but with 
p values of 0.10 and 0.36 respectively, depriving these results from their significance 
(Voight et al. 2010).   
The main distinction between the studies achieved to determine the impact of 
these mutations in T2D pathogenesis, is the fact that the treatment options constituted 
the points of repair criteria of our work. Whereas Voight et al. (2010) choose to directly 
assay the fasting insulin levels, therefore providing a better perspective to more reliable 
and significant results.  
Finally, the main handicap is the small volume of cases and controls enrolled in 
our study and the small number in the subgroups formed when analyzing the 
associations between the mutations and the risk factor for T2D. This may reflect an 
imprecise approximation of the magnitudes of the observed results. Also, the poor 
 -29- 
available information on BMI, lipid profile and medication could have limited the effect 
assessment of these variables in determining their association with the mutations of 
interest. 
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CHAPTER 5 
CONCLUSION 
 
Type 2 diabetes, a chronic metabolic condition, is the result of the interaction 
between several genes and the environment. Significant progress has been accomplished 
lately to identify new genes related to T2D pathogenesis.  
In this study, we were able to replicate the SNP rs7957197 in the HNF1-α region, 
in the Lebanese diabetic population. This polymorphism did not correlate neither with 
gender, family history of T2D, nor with obesity. However its risk allele, the T allele, 
was more common in diabetic subjects treated with OHA. As a result and since these 
patients do not require treatment with insulin injections , this rs7957197 in the HNF1-α 
region mutation, may be implicated in diminishing the rate of β cells.  
The other two SNP, rs972283 in KLF14 region and rs1531343 in HMGA2 region, 
were not associated with T2D in our population. However, the study revealed that the 
GG genotype of rs972283 is linked to the Lebanese diabetic patients not treated with 
insulin injections, implying its role in protection against a severe pancreatic β cell 
failure. 
Since these three SNP have been recently added to the genes linked with T2D 
pathogenesis, and because of a probable limitation due to our relative small sample size, 
further studies with a larger Lebanese population need to be accomplished. And this in 
order to replicate our findings and to highlight further on the risk factors of T2D such as 
BMI, family history and to explore the effect of the different oral hypoglycemic agents 
on gene polymorphism. 
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